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HLA matching and cadaver kidney
transplantation - status 1984
Gerhard Opelz, for the Collaborative Transplant Study
SUMMARY
The effectofHLA matchingoncadaverkidneygraftsurvival was analysedinover
9000 transplants. MatchingforHLA-A and -B accountedforan improvement of
8% in the one-year survival rate, matchingforHLA-DR for 10%, and matching
for HLA-B + DR for 19%. The matching effect ofthe HLA-B and HLA-DR loci
was additive. Patients without pre-transplant transfusions had lower graft
survival rates than transfused patients, even if their grafts were HLA matched.
The highestsuccess rate was obtained in transfusedrecipients who receivedHLA
matched kidneys.
INTRODUCTION
The relevance of HLA matching, although unquestioned in the related donor
situation where HLA identical siblings clearly represent an immunologically
privileged category with superior graft outcome, has been difficult to establish in
cadaver kidney transplantation. Conflicting reports have been published during
the past 15 years with respect to matching for the HLA-A and -B antigens. The
HLA-DR locus, which was introduced some five years ago, had a stronger effect
according to early reports than HLA-A or -B; however, this was notsubstantiated
in an international workshop study carried out in 1980.1 It was recognised at that
time that the technical quality of HLA-DR typing was less than satisfactory
because of early difficulties with the B cell isolation technique. The picture was
complicated further by a shift in transfusion policies in the late seventies and
early eighties. It had becomefirmly established that non-transfused recipients did
less well than transfused ones, and as a result the fraction of patients who
received transplants without transfusion pre-treatment decreased drastically.
Concurrently, typing techniques for HLA-DR were standardised and refined. The
need for a re-evaluation of HLA matching in cadaver kidney transplantation
became evident. In 1982, an international collaborative project wasinitiated, with
the primary purpose of establishing on a large multicentre basis whether HLA
matching had a place in modern renal transplantation. This report is an account
of the early results (up to one year) that were obtained in over 9000 patients
transplanted during the last two years.
METHODS
The data on which this analysis was based were gathered as part of the
Collaborative Transplant Study project. Two hundred and nine transplant centres
in the following cities participated: Angers, Atlanta, Barcelona, Basel, Belfast,
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Berlin-East, Berlin-West, Bern, Birmingham (Alabama), Boston, Bristol,
Brooklyn, Brussels, Budapest, Buenos Aires, Cambridge, Capetown, Cardiff,
Chiba, Chicago, Cincinnati, Cleveland, Cologne, Dallas, Detroit, Dublin, Ehime,
Erlangen, Essen, Frankfurt, Freiburg, Fukui, Fukuoka, Geneva, Glasgow,
Gothenburg, Groningen, Halifax, Halle, Hamamatsu, Hamburg, Hannover,
Hartford, Heidelberg, Helsinki, Hiroshima, Homburg, Hong Kong, Houston,
Innsbruck, Iowa City, Ishikawa, Kaiserslautern, Kanagawa, Kansas City,
Kashihara, Kiel, Kyoto, Lausanne, Leicester, Leningrad, Leuven, Lexington,
Lisbon, London, Louisville, Luebeck, Lyon, Maastricht, Madrid, Lund-Malmo,
Manchester, Marburg, Melbourne, Mexico City, Milan, Minneapolis, Montpellier,
Montreal, Moscow, Munster, Munich, Muroran, Nagasaki, Nancy, Nantes,
Nashville, New York, Newcastle, Nice, Nijmegen, Nishinomiya, Okayama,
Omaha, Osaka, Ottawa, Oxford, Paris, Perth, Phoenix, Piraeus, Portland, Porto
Alegre, Prague, Quebec, Rennes, Rio de Janeiro, Rochester (Minnesota),
Rochester (New York), Rome, Rostock, Saitama, San Antonio, San Francisco,
Santiago, Sapporo, Seattle, Shinagawa, St Etienne, St Louis, Sydney, Szeged,
Takatsuki, Tel Aviv, Thessaloniki, Tokyo, Toledo (Ohio), Torino, Toronto,
Toulouse, Tubingen, Ulm, Uppsala, Valencia, Vancouver, Villejuif, Vilnius,
Warsaw, Winnipeg, Zagreb, Zurich. Participation in this study was entirely
voluntary. The centres aqreed to provide information on all consecutive
transplants only. First cadaver trans-
plants performed between January
1982 and July 1984 were analysed.
All transplants had a minimum clinical
follow-up of 3 months. No exclusions
were made. Graft survival rates were
computed by actuarial methods. Stat-
istical significance was calculated by
weighted regression.2
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Fig. 1. Effect of matching for the HLA-A and
HLA-B locus antigens on kidney graft survival.
Actuarial survival rates are plotted for
transplants with 0, 1, 2, 3, or 4 mismatches.
Numbers of patients in each mismatch
category are indicated.
RESULTS
The effect on graft survival of matching
for HLA-A and -B is shown in Fig 1.
Although there is a stepwise decrease
in success rates from 0 to 4 mis-
matches, the difference between the
best and worst match grade is a
disappointing 8% at oneyear. Separate
analysis of the HLA-A and HLA-B loci
shows that there is little difference in
their individual weights (Fig 2).
Matchino for HLA.DR can be seen to
correlate with graft survival to aboutthe same degree as HLA-A and -B combined
(Fig 3). Although this degree of correlation is clinically useful, the discriminative
power of HLA DR alone is not asstrong asone would ultimatelywish to gain from
tissue typing.
Both the 8th and 9th International Histocompatibility Workshop analysesshowed
an additive affectofHLA-B and HLA-DRoncadaverkidneytransplantsurvival.1 3
The current analysis clearly supports this. A difference of 19% in the one-year
survival rates wasfound between graftswith 0 or4 HLA-B + DR mismatches, and
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Fig. 2. Separate analysis of influence on graft survival of the HLA.A or HLA-B loci. There was no
clear difference in strength between the two loci.
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Fig. 3. Effect of HLA-DR matching on cadaver
kidney graft survival. The correlation was
statistically highly significant (p <0.0001).
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Fig. 4. Combined effect of HLA-B + DR
matching on cadaver kidney graft survival. The
success rate declines stepwise from 0 to 4
mismatches. Statistical significance byweighted
regression: p < 0.0001.
the graft survival rates declined stepwise from 0 to 4 mismatches (Fig 4).
No significant further improvement was achieved by including HLA-A in the
analysis. The combined consideration ofthethree loci HLA-A + B + DR resulted
in a statistically highly significant correlation with graft survival; however, the
correlation was similar to that obtained with HLA-B + DR (Fig 5). Because it is
desirable for logistical reasons to limit the number of loci considered in the
selection process to the minimum necessary, matching for HLA-B + DR has an
obvious practical advantage over HLA-A + B + DR matching.
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Fig. 5. Combined analysis of HLA-A, HLA-B,
and HLA-DR loci. Grafts with 0 mismatches
had an approximately 20% higher survival rate
than grafts with 5 mismatches. The correlation
was not improved compared with the analysis
of HLA-B + DR.
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Fig. 6. Effect of pre-transplant transfusions
on survival of cadaver kidney transplants.
Patients without pre-transplant transfusions
clearlyhaveinferiorgraftoutcome. 1 transfusion
and > 20 transfusions result in intermediately
good success rates. Possibly, additional risk
factors play a role in patients who received
multiple transfusions.
Fig 6 shows the influence of pre-transplant transfusions on graft survival. Non-
transfused recipients have the lowest success rate, patients with one or with
multiple ( > 20) transfusions have an intermediate success rate, and the best graft
outcome is observed in patients with anything from 2 to 20 pre-transplant
transfusions.
A separate analysis of HLA-DR matching in transfused or non-transfused
recipients is shown in Fig 7. Even though DR matching correlates with graft
survival in both patient subsets, the effect of matching does not overcome the
transfusion effect. In other words, well matched transplants in non-transfused
recipients do not perform better than poorly matched transplants in transfused
recipients. The highest success rate is obtained in transfused patients who are
transplanted with HLA-DR matched kidneys (Fig 7). Unfortunately, the number
of non-transfused patients was too small to allow an extension of this type of
analysis to HLA-B + DR.
DISCUSSION
These preliminary results of the Collaborative Transplant Study show that HLA
matching has a definite place in cadaver kidney transplantation. It remains to be
seen whether the one-year results shown here will be valid also for the
transplants' long-term course. Based on previous work, one can assume that this
will be So.4-6 Surely, if a method is known whereby the success rate can be
improved by 20%, it must be utilised clinically.
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Fig. 7. Effect of HLA-DR matching in non-transfused and transfused cadaver kidney recipients.
There is a matching effect in both categories; however, matched grafts in non-transfused patients are
still doing worse than mismatched grants in transfused recipients.
The additive effect of the HLA-B and HLA-DR loci is confirmed in the current
analysis. It appears that matching for HLA-DR alone is notsufficient forobtaining
optimum results. HLA-A and -B matching is also insufficient, a fact that has long
been suspected. From a logistical standpoint, HLA-B + DR matching is not as
convenient as matching for HLA-DR alone; it is, however, less cumbersome than
HLA-A + B matching (at least forthe time being, the polymorphism of HLA-A is
greater than that of HLA-DR). Therefore, it should be possible to perform many
HLA-B + DR matched transplants using established organ-sharing procedures.
Our transfusion data indicate that the effect of matching can be enhanced by
administering transfusions prior to transplantation. Transfused patients receiving
HLA-DR matched grafts did exceedingly well, and we may anticipate that
transfused HLA-B + DR matched patients will do even better.
Already, this type of analysis seems outdated in the face ofcyclosporin, the new
powerful immunosuppressant. First reports based on small series of patients
suggestthat cyclosporin may be able to overcome both thetransfusion effect and
the effect of HLA matching.78 Quite to the contrary, preliminary data
(unpublished) ofthe Collaborative Transplant Study indicate thatthere is a strong
transfusion as well as HLA matching effect even with the use ofcyclosporin. With
the rapidly increasing numbers of transplants that are becoming available for
analysis (the Collaborative Transplant Studygrows at a rateofapproximately 800
additional transplants per month), this new controversy is certain to be resolved
within a yearortwo. Our experience with partially additive effects ofotherfactors
would make it seem likely that the improved success rates attributed to
cyclosporin might benefit even further from the addition oftransfusions and HLA
matching.
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